Patents by Inventor Sei Yong JUN

Sei Yong JUN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CELL/TISSUE-SPECIFIC CELL-PENETRATING ANTIBODIES
    Publication number: 20200385428
    Abstract: Presented herein are cyclic peptides that specifically bind to a cell surface molecule, thereby allowing cell/tissue-specific targeting. The cyclic peptides can be attached to an agent, for example, a polypeptide such as an antibody, e.g., a cell-penetrating antibody. Cyclic peptide-containing cell/tissue-specific cell-penetrating antibodies described herein are capable of targeted delivery in a cell type-specific or tissue-specific (i.e., cell/tissue-specific) manner. The cell/tissue-specific cell-penetrating antibodies described herein can be used as an effective anticancer agent for cancer that overexpresses a cell membrane protein that specifically binds to the fused cyclic peptides.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 10, 2020
    Applicant: ORUM THERAPEUTICS INC.
    Inventors: Yong Sung KIM, Ji Sun KIM, Jae Yeong PARK, Seong Wook PARK, Sei Yong JUN, Dong-Ki CHOI
  • Cell/tissue-specific cell-penetrating antibodies
    Patent number: 10787487
    Abstract: Presented herein are cyclic peptides that specifically bind to a cell surface molecule, thereby allowing cell/tissue-specific targeting. The cyclic peptides can be attached to an agent, for example, a polypeptide such as an antibody, e.g., a cell-penetrating antibody. Cyclic peptide-containing cell/tissue-specific cell-penetrating antibodies described herein are capable of targeted delivery in a cell type-specific or tissue-specific (i.e., cell/tissue-specific) manner. The cell/tissue-specific cell-penetrating antibodies described herein can be used as an effective anticancer agent for cancer that overexpresses a cell membrane protein that specifically binds to the fused cyclic peptides.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: September 29, 2020
    Assignee: ORUM THERAPEUTICS INC.
    Inventors: Yong Sung Kim, Ji Sun Kim, Jae Yeong Park, Seong Wook Park, Sei Yong Jun, Dong-Ki Choi
  • CELL/TISSUE-SPECIFIC CELL-PENETRATING ANTIBODIES
    Publication number: 20190389910
    Abstract: Presented herein are cyclic peptides that specifically bind to a cell surface molecule, thereby allowing cell/tissue-specific targeting. The cyclic peptides can be attached to an agent, for example, a polypeptide such as an antibody, e.g., a cell-penetrating antibody. Cyclic peptide-containing cell/tissue-specific cell-penetrating antibodies described herein are capable of targeted delivery in a cell type-specific or tissue-specific (i.e., cell/tissue-specific) manner. The cell/tissue-specific cell-penetrating antibodies described herein can be used as an effective anticancer agent for cancer that overexpresses a cell membrane protein that specifically binds to the fused cyclic peptides.
    Type: Application
    Filed: June 20, 2019
    Publication date: December 26, 2019
    Applicant: ORUM THERAPEUTICS INC.
    Inventors: Yong Sung KIM, Ji Sun KIM, Jae Yeong PARK, Seong Wook PARK, Sei Yong JUN, Dong-Ki CHOI